Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAB-21822 in KRAS G12C/STK11 co-mutated, KEAP1 wild-type advanced or metastatic non-small cell lung cancer
CTR20220492Phase 2Active
- Sponsor
- Jacobio Pharmaceuticals
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of glecirasib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Jacobio Pharmaceuticals. Primary endpoints: Safety and tolerability in dose escalation and Objective response rate in dose expansion. Started Aug 2022; status: active.
02
Drugs
glecirasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20220492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220492.